Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/172406
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.
Subject
Subject (English)
Citation
Citation
MONTES MORENO, Santiago, et al. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. Haematologica. 2014. Vol. 99, num. 8, pags. 138-141. ISSN 0390-6078. [consulted: 7 of June of 2026]. Available at: https://hdl.handle.net/2445/172406